Marton In Cleveland

Researchers are investigating how mitral valve prolapse (MVP) affects the heart's left ventricle, potentially leading to arrhythmias and sudden death. This study is an ancillary part of a larger trial comparing two treatments for degenerative mitral regurgitation: mitral valve repair (MVr) and transcatheter-edge-to-edge repair (TEER). The goal is to understand how these treatments impact heart muscle structure and function, with the hope of improving therapeutic strategies for different patient groups and reducing heart failure and arrhythmias. Participants in this study will undergo various evaluations including rhythm monitoring with a wearable ZioPatch device, cardiac magnetic resonance imaging (CMR) before and after the intervention, and transthoracic echocardiograms as part of the parent trial. Up to 60 patients undergoing surgical repair will also have tissue biopsies taken from the heart muscle during surgery. The study is conducted at specialized centers across the U.S., Canada, Germany, the U.K., and Spain, with an enrollment period of 12 to 18 months. Throughout the study, participants will be monitored from baseline until one year after their procedure. Researchers will assess the presence of myocardial fibrosis, ventricular arrhythmias, and changes in heart structure using advanced imaging and tissue analysis. They will also analyze gene products and clinical outcomes to better predict and understand treatment responses. This comprehensive approach aims to provide detailed insights into how different repair methods affect the heart over time.